Headlines about Bruker Corporation (NASDAQ:BRKR) have been trending somewhat positive on Saturday, Accern reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Bruker Corporation earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave headlines about the medical research company an impact score of 45.4302876354198 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
- Edited Transcript of BRKR earnings conference call or presentation 3-Aug-17 8:30pm GMT (finance.yahoo.com)
- Bruker (BRKR) Q2 Earnings & Revenues Beat Estimates, View Up (finance.yahoo.com)
- Bruker (BRKR) Q2 2017 Results - Earnings Call Transcript (seekingalpha.com)
- Bruker Corporation (NASDAQ:BRKR) Announces Quarterly Earnings Results, Beats Expectations By $0.03 EPS (americanbankingnews.com)
- Bruker Corporation (NASDAQ:BRKR) Updates FY17 Earnings Guidance (americanbankingnews.com)
Shares of Bruker Corporation (BRKR) opened at 27.88 on Friday. The firm has a market cap of $4.45 billion, a P/E ratio of 29.60 and a beta of 1.10. The stock has a 50 day moving average price of $28.70 and a 200 day moving average price of $25.43. Bruker Corporation has a 12-month low of $19.58 and a 12-month high of $30.22.
Bruker Corporation (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, August 3rd. The medical research company reported $0.23 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.03. Bruker Corporation had a return on equity of 27.18% and a net margin of 9.65%. The business had revenue of $414.90 million during the quarter, compared to the consensus estimate of $384.75 million. During the same quarter in the prior year, the company posted $0.20 earnings per share. Bruker Corporation’s revenue was up 11.6% compared to the same quarter last year. On average, equities analysts expect that Bruker Corporation will post $1.10 earnings per share for the current year.
Bruker Corporation declared that its Board of Directors has initiated a share repurchase plan on Friday, May 12th that allows the company to repurchase $225.00 million in shares. This repurchase authorization allows the medical research company to buy shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.
Several brokerages have recently weighed in on BRKR. BidaskClub cut shares of Bruker Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Barclays PLC reaffirmed an “equal weight” rating and set a $30.00 price target (up from $26.00) on shares of Bruker Corporation in a research note on Monday, July 17th. Jefferies Group LLC reaffirmed a “buy” rating and set a $29.00 price target on shares of Bruker Corporation in a research note on Monday, May 15th. Wells Fargo & Company cut shares of Bruker Corporation from a “market perform” rating to an “underperform” rating in a research note on Wednesday, July 12th. Finally, Deutsche Bank AG raised their price target on shares of Bruker Corporation from $25.00 to $27.00 and gave the stock a “hold” rating in a research note on Monday, May 15th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $27.00.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Bruker Corporation (NASDAQ:BRKR) Stock Price” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://stocknewstimes.com/2017/08/05/bruker-corporation-nasdaqbrkr-earns-daily-coverage-optimism-score-of-0-21-updated.html.
In other Bruker Corporation news, CEO Frank H. Laukien acquired 73,000 shares of Bruker Corporation stock in a transaction on Thursday, May 18th. The stock was purchased at an average price of $26.22 per share, for a total transaction of $1,914,060.00. Following the purchase, the chief executive officer now directly owns 37,750,851 shares of the company’s stock, valued at $989,827,313.22. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Ingen Chris Van sold 19,900 shares of the company’s stock in a transaction on Wednesday, June 14th. The shares were sold at an average price of $28.03, for a total value of $557,797.00. Following the completion of the transaction, the director now owns 14,577 shares of the company’s stock, valued at approximately $408,593.31. The disclosure for this sale can be found here. In the last 90 days, insiders acquired 78,120 shares of company stock valued at $2,047,366 and sold 117,624 shares valued at $3,271,574. 35.20% of the stock is owned by corporate insiders.
About Bruker Corporation
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
